Navigation Links
Pharmasset to Present at Two Upcoming Investor Conferences
Date:11/10/2008

PRINCETON, N.J., Nov. 10 /PRNewswire-FirstCall/ -- Pharmasset, Inc. (Nasdaq: VRUS) announces management will present at the Rodman and Renshaw 10th Annual Global Investment Conference and the Lazard Capital Markets 5th Annual Healthcare Conference. Both conferences will be held in New York, NY.

Schaefer Price, Pharmasset's President and Chief Executive Officer, will provide an overview of the company at the Rodman and Renshaw Conference on Tuesday, November 11, 2008 at 12:25 PM (ET) and at the Lazard Capital Markets Conference on Tuesday November 18, 2008 at 8:55 AM (ET)

To access a simultaneous webcast of Mr. Price's overview via the internet, log on to the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm . Please connect to the website at least ten minutes prior to the start of the presentation to ensure adequate time for a reliable connection and any software download that may be necessary for the webcast.

A replay of the webcast will be available on Pharmasset's website for thirty days following the conference. The investor presentation will be available for download in PDF format immediately following the presentation in the "Events & Presentations" section of the Investor Center on Pharmasset's website at http://investor.pharmasset.com/events.cfm .

About Pharmasset

Pharmasset is a clinical-stage pharmaceutical company committed to discovering, developing and commercializing novel drugs to treat viral infections. Pharmasset's primary focus is on the development of oral therapeutics for the treatment of hepatitis B virus (HBV), hepatitis C virus (HCV) and human immunodeficiency virus (HIV).

Pharmasset is currently developing three product candidates. Clevudine, for the treatment of chronic HBV infection, is enrolling Phase 3 clinical trials for registration in North, Central and South America and Europe. Clevudine is already approved for HBV in South Korea and marketed by Bukwang Pharmaceuticals in South Korea under the brand name Levovir. R7128, an oral treatment for chronic HCV infection, has completed a 4-week clinical trial in combination with Pegasys(R) plus Copegus(R) through a strategic collaboration with Roche. Racivir, which is being developed for the treatment of HIV in combination with other approved HIV drugs, has completed a Phase 2 clinical trial.

Pegasys(R) and Copegus(R) are registered trademarks of Roche.

Contact

Richard E. T. Smith, Ph.D.

VP, Investor Relations and Corporate Communications

richard.smith@pharmasset.com

Office: +1 (609) 613-4181

Forward-Looking Statements

Pharmasset "Safe Harbor" Statement under the Private Securities Litigation Reform Act of 1995: Statements in this press release regarding our business that are not historical facts are "forward-looking statements" that involve risks and uncertainties, including without limitation, the risk that adverse events could cause the cessation or delay of any of the ongoing or planned clinical trials and/or our development of our product candidates, the risk that the results of previously conducted studies involving our product candidates will not be repeated or observed in ongoing or future studies involving our product candidates, the risk that our collaboration with Roche will not continue or will not be successful and the risk that any one or more of our product candidates will not be successfully developed and commercialized. For a discussion of these risks and uncertainties, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section of our Annual Report on Form 10-K for the fiscal year ended September 30, 2007 filed with the Securities and Exchange Commission entitled "Risk Factors" and discussions of potential risks and uncertainties in our subsequent filings with the Securities and Exchange Commission.


'/>"/>
SOURCE Pharmasset, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Related biology technology :

1. Pharmasset to Present at the Natixis Bleichroeder Hidden Gems Conference on Monday, October 13th
2. Pharmasset to Present at the JMP Securities Healthcare Focus Conference on Monday, October 6th
3. Pharmasset Reports Preliminary Results of a 4-week Proof-of-Concept Combination Study of R7128 for the Treatment of Chronic Hepatitis C in Genotype 2 or 3 Non-Responders
4. Pharmasset to Present at the Upcoming Citibank and Morgan Stanley Investor Conferences
5. Pharmasset to Present at the Canaccord Adams Global Growth Conference on Tuesday, August 12th
6. Pharmasset Announces $25.9 Million Registered Direct Offering of Common Stock
7. Pharmasset Joins Russell 3000 Index
8. Pharmasset to Present at the Needham & Co. Biotechnology and Medical Technology Conference on Wednesday, June 11th
9. Pharmasset Selected to Join the NASDAQ Biotechnology Index
10. Pharmasset to Present at the Morgan Stanley Global Healthcare Conference on Wednesday, April 30th
11. Pharmasset Adds Two Cohorts to R7128 Hepatitis C Study
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/26/2016)... CAMBRIDGE, Mass. (PRWEB) , ... April 26, 2016 , ... ... Herr has been selected as one of three finalists for the European Inventor ... the EPO’s annual innovation prize will be announced at a ceremony in Lisbon on ...
(Date:4/26/2016)... , ... April 26, 2016 , ... Mr. Palmer created ... RPO, signing the first multi-million dollar, multi-year managed services contract in the U.S. intelligence ... Michael join our leadership team,” said John Younger, founder of Accolo. “We are ...
(Date:4/26/2016)... , ... April 26, 2016 , ... BioFactura, Inc ... Series A round of financing. Healthy investor interest drove significant oversubscription of the ... generic biologics, known as biosimilars, to the advanced preclinical stages. , Chief Executive Officer ...
(Date:4/26/2016)... , VIENNA and ... -- The prize recognizes the innovation ... revolutionary innovations that will benefit patients and laboratory ... ) , Norma Instruments ... trend setting products in the field of hematology, ...
Breaking Biology Technology:
(Date:3/3/2016)... , March 3, 2016  2016FLEX, organized by ... week highlighting advancements in flexible, hybrid and printed ... setting attendance - have gathered for short courses, ... field of electronics. The Flex Conference celebrates its ... for companies, R&D organizations, and universities contributing to ...
(Date:3/2/2016)... DUBLIN , March 2, 2016 /PRNewswire/ ... has announced the addition of the  "Global ... to their offering.  ,     (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ... sector to grow at a CAGR of ... http://www.researchandmarkets.com/research/wzwqtz/global_biometrics ) has announced the addition ...
(Date:3/1/2016)... March 1, 2016 ... addition of the  "Global Biometric Access ... to their offering. --> ... of the  "Global Biometric Access Control ... their offering. --> Research ...
Breaking Biology News(10 mins):